Study shows higher risk of inhibitors in children using recombinant vs. plasma-derived factor VIII products to treat severe hemophilia A.
NHF's MASAC issues two new documents, one on treatment recommendations and the other on physical therapy guidelines.
FDA approves Baxalta's Vonvendi, the first recombinant von Willebrand factor therapy for patients with VWD.
Rice University researchers confirm the presence of factor VIII in endothelial cells, a potential site for future gene therapy.
NHF and CDC work together to improve inhibitor screening and testing, after data show true prevalence among people with hemophilia.
HTRS announces two new clinical fellowship awards in 2016 for MDs or DOs interested in focusing on hemophilia and/or other rare bleeding disorders.
FDA approves Baxalta's ADYNOVATE, a new longer- lasting recombinant factor VIII product for people with hemophilia A.
MASAC issues new recommendation on inhibitor testing and surveillance for patients with hemophilia A and B, based on CDC study findings.
Latest Medscape educational opportunity for healthcare providers is on inhibitor management.
Latest Nurses Guide chapter focuses on factor concentrates and other treatments for patients with hemophilia A or B.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car